Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice
fa-facebookfa-linkedinfa-youtube-playfa-rss

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Arkansas Leads the Nation with Landmark Pharmacy Benefit Manager Reform

Joseph Cantrell, JD  |  June 22, 2025

Arkansas has taken bold action to restore transparency and fairness to the prescription drug system by enacting HB 1150 (Act 624), legislation that prohibits pharmacy benefit managers (PBMs) from owning or operating retail and mail-order pharmacies in the state.

Signed into law by Gov. Sarah Huckabee Sanders in April, the legislation addresses longstanding concerns about conflicts of interest, market consolidation and patient access created by vertically integrated PBM pharmacy models. The law takes effect on Jan. 1, 2026, and sets a national precedent for reining in PBM dominance over drug pricing and distribution.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Strengthening Oversight & Ending Self-Dealing

At the core of HB 1150 is a simple principle: PBMs should not be allowed to profit from controlling both the price and the delivery of prescription medications. By banning direct and indirect PBM ownership of pharmacies, the law aims to restore a level playing field for independent pharmacies and increase choice for patients and prescribers.

Under the law:

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE
  • PBM-affiliated pharmacies must be divested by Jan. 1, 2026;
  • The Arkansas State Board of Pharmacy will identify permit violations by July 1, 2025; and
  • Affected pharmacies must notify patients and prescribers at least 60 days in advance of permit loss.

Importantly, the law includes limited-use permits and patient safeguards during the transition, including carve-outs for rare and orphan drug distribution and provisions for urgent-care pharmacy continuity.

Protecting Access for Patients & Providers

For rheumatologists and patients with complex, chronic diseases, HB 1150 offers a vital course correction. PBM-owned specialty pharmacies have often restricted medication access through opaque formulary design, limited networks and exclusive dispensing contracts. These practices have created unnecessary delays, confusion and financial hardship for patients living with rheumatologic disease.

Supporting Rural & Independent Pharmacies

HB 1150 is also a victory for local pharmacies that have been squeezed out of PBM networks or forced to accept unsustainable reimbursement rates. Many independent and rural pharmacies, often the only accessible healthcare provider in their communities, have long advocated for reforms to limit PBM overreach.

By banning vertical integration, Arkansas is opening the door to more pharmacy options and community-based solutions for patients. The law’s limited exceptions ensure that patients receiving rare or limited-distribution drugs are not left behind during the transition.

Setting a National Example

Arkansas’ leadership reflects growing bipartisan momentum across the country to reform PBM practices. The passage of HB 1150 aligns with calls from 39 state attorneys general urging Congress to dismantle monopolistic pharmacy ownership structures and pass federal legislation such as the Patients Before Middlemen Act.

Other states are already considering similar reforms, signaling that Arkansas’ approach could become a model for nationwide PBM accountability. However, those reforms could be delayed or derailed pending the outcome of a recently filed lawsuit.

The Pharmaceutical Care Management Association (PCMA), the national PBM trade group, is challenging the law’s constitutionality. The group argues it violates the Commerce Clause by discriminating against out-of-state companies and the Privileges and Immunities Clause by favoring in-state pharmacies. While a final disposition will not be known for quite some time, it would not be surprising for a temporary injunction to be issued to prevent the implementation of the Arkansas law until the case has worked its way through the legal process.

Conclusion

HB 1150 represents a decisive step toward a more transparent and equitable prescription drug system. By separating PBM business interests from pharmacy ownership, Arkansas is prioritizing patients, supporting providers and promoting a healthcare marketplace built on fairness while fighting against vertical integration and monopolistic business models.


Joseph Cantrell, JD, is the director of state affairs and community relations for the ACR.

Share: 

Filed under:Legal UpdatesLegislation & Advocacy Tagged with:pharmacy benefit managers (PBMs)state legislation

Related Articles

    Florida Law Puts Drug Pricing by Pharmacy Benefit Managers Under a Microscope Once Again

    August 8, 2022

    As of July 1, a Florida bill increases oversight of pharmacy benefit managers and offers some protection for pharmacies. However, the legislation has limited effects on patients and providers, highlighting the need for additional reform.

    Arkansas PBM Bill: A Step in the Right Direction

    April 4, 2018

    During a three-day special legislative session in March, Arkansas Governor Asa Hutchinson (R) signed into law the first bill in the U.S. intended to address a lack of transparency among pharmacy benefit managers (PBMs) and their role in the high cost of prescription drugs.1 The bill, H.B. 1010: Arkansas Pharmacy Benefits Manager Licensure Act, will…

    Pharmacy Benefit Managers Under Scrutiny

    June 10, 2024

    “When pharmacy benefit managers [PBMs] came into being 30 years ago, they were seen as an important component of the prescription distribution system [because] they could guide benefits and money between the patient, pharmacy and the manufacturer,” says Angus Worthing, MD, president of the Alliance for Transparent & Affordable Prescriptions (ATAP). Health insurance companies hire…

    U.S. Drug Benefit Managers Clamp Down on Specialty Pharmacies

    November 17, 2015

    NEW YORK/LOS ANGELES (Reuters)—In recent days, the largest U.S. managers of private prescription drug benefits have cut off at least eight pharmacies that work closely with drugmakers, intensifying scrutiny of a system that helps inflate drug prices, officials at the benefit managers told Reuters. The terminations come from payers who together manage drug benefits for…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
fa-facebookfa-linkedinfa-youtube-playfa-rss
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences